177 related articles for article (PubMed ID: 9749583)
1. Neuroprotective and neurorestorative properties of GDNF.
Gash DM; Zhang Z; Gerhardt G
Ann Neurol; 1998 Sep; 44(3 Suppl 1):S121-5. PubMed ID: 9749583
[TBL] [Abstract][Full Text] [Related]
2. Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease.
Grondin R; Gash DM
J Neurol; 1998 Nov; 245(11 Suppl 3):P35-42. PubMed ID: 9808338
[TBL] [Abstract][Full Text] [Related]
3. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle.
Rosenblad C; Kirik D; Devaux B; Moffat B; Phillips HS; Björklund A
Eur J Neurosci; 1999 May; 11(5):1554-66. PubMed ID: 10215908
[TBL] [Abstract][Full Text] [Related]
4. Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease.
Voutilainen MH; Bäck S; Pörsti E; Toppinen L; Lindgren L; Lindholm P; Peränen J; Saarma M; Tuominen RK
J Neurosci; 2009 Jul; 29(30):9651-9. PubMed ID: 19641128
[TBL] [Abstract][Full Text] [Related]
5. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor.
Kirik D; Rosenblad C; Björklund A
Eur J Neurosci; 2000 Nov; 12(11):3871-82. PubMed ID: 11069582
[TBL] [Abstract][Full Text] [Related]
6. Intranigral ventral mesencephalic grafts and nigrostriatal injections of glial cell line-derived neurotrophic factor restore dopamine release in the striatum of 6-hydroxydopamine-lesioned rats.
Tang FI; Tien LT; Zhou FC; Hoffer BJ; Wang Y
Exp Brain Res; 1998 Apr; 119(3):287-96. PubMed ID: 9551829
[TBL] [Abstract][Full Text] [Related]
7. GDNF administration induces recovery of the nigrostriatal dopaminergic system both in young and aged parkinsonian mice.
Date I; Aoi M; Tomita S; Collins F; Ohmoto T
Neuroreport; 1998 Jul; 9(10):2365-9. PubMed ID: 9694229
[TBL] [Abstract][Full Text] [Related]
8. A preclinical development strategy designed to optimize the use of glial cell line-derived neurotrophic factor in the treatment of Parkinson's disease.
Lapchak PA
Mov Disord; 1998; 13 Suppl 1():49-54. PubMed ID: 9613719
[TBL] [Abstract][Full Text] [Related]
9. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys.
Miyoshi Y; Zhang Z; Ovadia A; Lapchak PA; Collins F; Hilt D; Lebel C; Kryscio R; Gash DM
Ann Neurol; 1997 Aug; 42(2):208-14. PubMed ID: 9266731
[TBL] [Abstract][Full Text] [Related]
10. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys.
Grondin R; Zhang Z; Yi A; Cass WA; Maswood N; Andersen AH; Elsberry DD; Klein MC; Gerhardt GA; Gash DM
Brain; 2002 Oct; 125(Pt 10):2191-201. PubMed ID: 12244077
[TBL] [Abstract][Full Text] [Related]
11. Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets.
Costa S; Iravani MM; Pearce RK; Jenner P
Eur J Pharmacol; 2001 Jan; 412(1):45-50. PubMed ID: 11166735
[TBL] [Abstract][Full Text] [Related]
12. Adenoviral vector-mediated delivery of glial cell line-derived neurotrophic factor provides neuroprotection in the aged parkinsonian rat.
Connor B
Clin Exp Pharmacol Physiol; 2001 Nov; 28(11):896-900. PubMed ID: 11703392
[TBL] [Abstract][Full Text] [Related]
13. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.
Björklund A; Kirik D; Rosenblad C; Georgievska B; Lundberg C; Mandel RJ
Brain Res; 2000 Dec; 886(1-2):82-98. PubMed ID: 11119690
[TBL] [Abstract][Full Text] [Related]
14. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.
Rosenblad C; Kirik D; Björklund A
Exp Neurol; 2000 Feb; 161(2):503-16. PubMed ID: 10686072
[TBL] [Abstract][Full Text] [Related]
15. Histological effects of intraputaminal infusion of glial cell line-derived neurotrophic factor in Parkinson disease model macaque monkeys.
Oiwa Y; Nakai K; Itakura T
Neurol Med Chir (Tokyo); 2006 Jun; 46(6):267-75; discussion 275-6. PubMed ID: 16794346
[TBL] [Abstract][Full Text] [Related]
16. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo.
Kearns CM; Gash DM
Brain Res; 1995 Feb; 672(1-2):104-11. PubMed ID: 7749731
[TBL] [Abstract][Full Text] [Related]
17. Effects of glial cell line-derived neurotrophic factor on the nigrostriatal dopamine system in rodents and nonhuman primates.
Gash DM; Gerhardt GA; Hoffer BJ
Adv Pharmacol; 1998; 42():911-5. PubMed ID: 9328046
[No Abstract] [Full Text] [Related]
18. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system.
Kirik D; Rosenblad C; Bjorklund A; Mandel RJ
J Neurosci; 2000 Jun; 20(12):4686-700. PubMed ID: 10844038
[TBL] [Abstract][Full Text] [Related]
19. Glial cell line-derived neurotrophic factor prevents death, but not reductions in tyrosine hydroxylase, of injured nigrostriatal neurons in adult rats.
Lu X; Hagg T
J Comp Neurol; 1997 Nov; 388(3):484-94. PubMed ID: 9368855
[TBL] [Abstract][Full Text] [Related]
20. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.
Kordower JH; Emborg ME; Bloch J; Ma SY; Chu Y; Leventhal L; McBride J; Chen EY; Palfi S; Roitberg BZ; Brown WD; Holden JE; Pyzalski R; Taylor MD; Carvey P; Ling Z; Trono D; Hantraye P; Déglon N; Aebischer P
Science; 2000 Oct; 290(5492):767-73. PubMed ID: 11052933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
